Eisai got an exclusive right to sell Gilead’s rheumatism drug in Japan

In Corporate
December 24, 2019
E

The American pharmaceutical company Gilead and the Japanese company Eisai have concluded a distribution and marketing agreement for the drug filgotinib for the treatment of rheumatism in Japan. Financial details were not provided.

Gilead is responsible for the production and market approval of filgotinib. Eisai is going to distribute the drug. Gilead is the cooperation partner of the biotechnologist Galapagos, listed on the stock exchange in Amsterdam. The two previously signed a deal about the development and marketing of filgotinib.

By: Peretz M.

Peretz M. is an accomplished economist and financial journalist with a deep understanding of the global economy and financial markets. He is a regular contributor to EconomicInform, where he provides expert analysis and commentary on current economic trends and events. With a strong educational background in economics, Peretz has a talent for breaking down complex economic concepts for a general audience and is able to provide insightful perspectives on a wide range of economic issues.

Add comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Read more

4 days ago

Rising costs and intense competition led BCC to bankruptcy

2 Min read
Add comment
22September

The administrators of BCC have filed for bankruptcy. Due to increasing costs and customer cutbacks, the curtain is now falling for the electronics retail chain. The administrators of BCC informed the employees on Thursday morning that they have applied for bankruptcy for the electronics retail chain. BCC had already been granted a suspension of payments last week, and bankruptcy often follows...

1 month ago

Ripple Vs. SEC: the saga isn’t over yet

3 Min read
Add comment
25August

In the ongoing legal saga between Ripple Labs and the US Securities and Exchange Commission (SEC), Judge Analisa Torres has made critical announcements regarding the upcoming trial dates and associated deadlines. Upcoming Deadlines for Ripple Vs. SEC In a filing on August 9th with the US District Court for the Southern District of New York, Judge Torres expressed her intention to proceed with a...

1 month ago

Philips sold over 12 percents to Agnelli family

4 Min read
Add comment
18August

Exor, the investment fund owned 53% by the Italian Agnelli family (Fiat), initially purchased nearly 3% of Philips, and last Sunday, through an investment bank, acquired over 12%. It’s a noteworthy transaction, particularly from Exor’s perspective. The deal itself was a swift move, as spokespeople from Philips and Exor have indicated: “On Sunday, Exor signed the agreement with...

2 months ago

Apple Reports Decline in iPhone, Mac, and iPad Sales

2 Min read
Add comment
04August

Apple sold fewer iPhones, Macs, and iPads in the last quarter, leading to a decline in the company’s total revenue for the third consecutive quarter. However, there was a bright spot for Apple in the sales of digital products, such as subscriptions to Apple Music and iCloud. Particularly disappointing was the iPhone sales, which were over 2 percent lower compared to the same quarter last...

By Leah Kunze December 24, 2019
Add comment

Recent Posts

Categories

About us

EconomicInform, EconomicInform.com is a product of EconomicInform LLC. We sincerely believe that economics is one of the most interesting and most underappreciated – in terms of getting some enjoyment out of reading the subject articles – sciences. More on that - at the link. Feel free to drop us a line.